	e:May 10 th , 2021		
	r Name: Sijia Ren		
	-	eview of primary research	endpoints of neoadjuvant therapy for lung cancer: past,
pres	ent and future		
Man	nuscript number (if known):	TLCR-21-259	
relate to trelate man. The to the med. In its	ted to the content of your mies whose interests may be cansparency and does not not it in the following questions apply to cuscript only. author's relationships/activite epidemiology of hyperterication, even if that medical	nanuscript. "Related" mear affected by the content of ecessarily indicate a bias. It is preferable that you do so the author's relationship rities/interests should be dension, you should declare a tion is not mentioned in the port for the work reported	s/activities/interests as they relate to the <u>current</u> <u>efined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
		Time name: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	X None	
	,		
4	Consulting fees	XNone	

			I
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	Stock of Stock options		
12	Possint of aguinment	X None	
12	Receipt of equipment, materials, drugs, medical	^_None	
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

Sijia Ren has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:____May 10th, 2021____

You	r Name: Anyi Xu		
Mai	nuscript Title:_ A narrative r	eview of primary research	endpoints of neoadjuvant therapy for lung cancer: past,
pres	sent and future		
-	nuscript number (if known):	TLCR-21-259	
In the relation to the relatio	he interest of transparency, ted to the content of your makes whose interests may be ransparency and does not not tionship/activity/interest, it following questions apply to muscript only. author's relationships/activity epidemiology of hyperterestication, even if that medical	we ask you to disclose all reparts of the author's relationship rities/interests should be declared to the not mentioned in the port for the work reported	s/activities/interests as they relate to the <u>current</u> lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

Anyi Xu has no conflicts of interest to declare.	

Please place an "X" next to the following statement to indicate your agreement:

Date:____May 10th, 2021____

You	r Name: Yilian Lin		
Maı	nuscript Title:_ A narrative r	eview of primary research	endpoints of neoadjuvant therapy for lung cancer: past,
pres	sent and future		
Mai	nuscript number (if known):	TLCR-21-259	
In the relation to the relatio	he interest of transparency, ted to the content of your makes whose interests may be ransparency and does not not tionship/activity/interest, it following questions apply to muscript only. author's relationships/activity epidemiology of hypertendication, even if that medical	we ask you to disclose all reparts of the author's relationship rities/interests should be declared to the not mentioned in the port for the work reported	es/activities/interests as they relate to the <u>current</u> <u>lefined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5 Payment or honoraria for		XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
0	testimony		
	testimon,		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10	Advisory Board	V. Nana	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	, , , , , , , , , , , , , , , , , , , ,		
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

Yilian Lin has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Da	te:	3/18/2021		
			oss Camidge	
Ma	nuscript	: Title: A narrative re	eview of primary research	endpoints of neoadjuvant therapy for lung cancer: past,
pre	sent and	d future		
Ma	nuscript	: number (if known)	: TLCR-21-259	
rela par to rela	ated to to ties who transpar ationship	the content of your ose interests may be ency and does not ro/activity/interest,	manuscript. "Related" mea e affected by the content o necessarily indicate a bias. it is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. ps/activities/interests as they relate to the current
	nuscript			
to i	the epid dication tem #1 l	emiology of hyperton, even if that mediconocless.	ension, you should declare ation is not mentioned in t	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other items
			Name all entities with	Specifications/Comments
			whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
			Time frame: Since the initial	planning of the work
1	All supp	ort for the present	X None	
	manusci provisio medical processi	ript (e.g., funding, n of study materials, writing, article ng charges, etc.) limit for this item.		
			Time frame: past	36 months
2	any enti	or contracts from ty (if not indicated ‡1 above).	XNone	
3	Royaltie	s or licenses	XNone	
4	Consulti	ng fees	XNone	

Payment or honoraria for	XNone	
T		
manuscript writing or		
educational events		
	XNone	
testimony		
Support for attending	X None	
meetings and/or travel		
Patents planned, issued or	XNone	
pending		
Participation on a Data	V None	
The state of the s	XNone	
Advisory Board		
Leadership or fiduciary role	XNone	
•		
	X None	
•		
	XNone	
=		+
services		
Other financial or non-	XNone	
financial interests		
		llowing box:
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or nonXNone

Please place an "X" next to the following statement to indicate your agreement:

Date:	30 Mar 2021
Your Nan	ne: Massimo Di Maio
Manuscri	pt Title: A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past
present a	and future
Manuscri	pt number (if known): TLCR-21-259

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	All I C II	Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	V None	
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
14	materials, drugs, medical	^NONE	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
DI.		fl: -4 - f : 4 4 ! 4 l	falleriine harr

Dr. Di Maio has no conflicts of interest to de	clare.

Please place an "X" next to the following statement to indicate your agreement:

Date: 19/3	/21_
Your Name:	Raffaele Califano
Manuscript Titl present and fut	e: A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, ure
Manuscript nur	nber (if known): TLCR-21-259
related to the o	of transparency, we ask you to disclose all relationships/activities/interests listed below that are ontent of your manuscript. "Related" means any relation with for-profit or not-for-profit third

parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	
4	Consulting fees	AZ, MSD, Roche and BMS	Personal payment

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	AZ, MSD, Roche and BMS XNone	Personal payment
7	Support for attending meetings and/or travel	Roche and MSD	
8	Patents planned, issued or pending	_XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	AZ, MSD, Roche and BMS	Personal payment
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_XNone	
11	Stock or stock options	_XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_XNone	
13	Other financial or non- financial interests	_XNone	

Dr. Califano has received honoraria for lectures, presentations, speakers bureaus, educational events and advisory boards from Astrazeneca, Roche, BMS and MSD, and support for attending meetings and/or travel from MSD and Roche, outside the submitted work.

Please place an "X" next to the following statement to indicate your agreement:

Date:____18 Mar 2021_

Yo	ur Name:Toyoaki Hida			
		e review of primary resear	ch endpoints of neoadjuvant therapy for lung cancer: pa	st,
pre	esent and future			
Ma	anuscript number (if known)	: TLCR-21-259		
In the relation of the relatio	the interest of transparency ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply muscript only. e author's relationships/activity epidemiology of hypertedication, even if that medicitem #1 below, report all sup	we ask you to disclose all manuscript. "Related" me affected by the content on necessarily indicate a bias. it is preferable that you do to the author's relationship ivities/interests should be ension, you should declare that it is not mentioned in apport for the work reporter.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a o so. ps/activities/interests as they relate to the current defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensiv	е
the	e time frame for disclosure is	s the past 36 months.		
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initia	l planning of the work	
1	All support for the present	XNone		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		-: :	25 1	
2	Grants or contracts from	Time frame: past	36 Months	
2	any entity (if not indicated	XNone		
	in item #1 above).			
3	Royalties or licenses	X None		
	no fairies of neclises			
4	Consulting fees	XNone		

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society,	XNone
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical	XNone
	writing, gifts or other services	
13	Other financial or non-	X None
	financial interests	
Ple		onflict of interest in the following box:
	Dr. Hida has no conflicts of in	terest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:M	arch 17, 2021
Your Name	:Antonio Rossi
Manuscript	t Title: A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past
present and	d future
Manuscript	t number (if known): TLCR-21-259

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initialXNone	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

	Т	1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	_XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
0	pending planned, issued or	^_NOTE	+
	Penung		+
9	Participation on a Data	X None	
J	Safety Monitoring Board or	^_None	
	Advisory Board		
10	•	X None	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
TT	Stock of Stock options		
12	Receipt of equipment,	X None	
17	materials, drugs, medical	^_NOTIE	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		
	.mandar miceresis		
ρlε	ease summarize the above co	anflict of interest in the fo	allowing hox:
rΚ	Jase Janninanze the above t	ominat of interest in the It	onouning work
Γ	Dr. Rossi has no conflicts of inte	arest to declare	
	DI. ROSSI has no conflicts of interest to decidie.		

Please place an "X" next to the following statement to indicate your agreement:

Da	te: March 31, 2021 __			
Yo	ur Name: Nicola	s Guibert		
Ma	nuscript Title: A narrative r	eview of primary research	endpoints of neoadjuvant therapy for lung cancer: past,	
pre	esent and future			
Ma	nuscript number (if known)	:_ TLCR-21-259		
In the relation of the relations of the	the interest of transparency ated to the content of your ries whose interests may be transparency and does not e ationship/activity/interest, e following questions apply inuscript only. e author's relationships/activite epidemiology of hypertedication, even if that medications are content and	we ask you to disclose all manuscript. "Related" med affected by the content on the constant of the content of the content of the content of the author's relationship ivities/interests should be ension, you should declare that it is not mentioned in the content of the content	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. ps/activities/interests as they relate to the current defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive	
	e time frame for disclosure i	• •	Specifications/Comments	,
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initia	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: past	36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
3	Royalties or licenses	XNone		
4	Consulting fees	Astra Zeneca, Roche, BMS,		

MSD, AMGEN, Novartis,

		,	
		Pfizer, Chiesi	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Astra Zeneca, Roche, BMS, MSD, AMGEN, Novartis, Pfizer, Chiesi	
6	Payment for expert	AMGEN, PulmonX	
	testimony		
7	Support for attending meetings and/or travel	Astra Zeneca, Roche, BMS, MSD, AMGEN, Novartis, Pfizer, Chiesi	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
	Cook of Sook opins		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Dr. Guibert reports personal fees from Astra Zeneca, Roche, BMS, MSD, AMGEN, Novartis, Pfizer, Chiesi, outside the
submitted work.

Please place an "X" next to the following statement to indicate your agreement:

Date	e:May 10 th , 2021		
	r Name: Chenchu Zhu	=	
Mar	uscript Title:_ A narrative r	eview of primary research	endpoints of neoadjuvant therapy for lung cancer: past,
-	present and future		
Mar	uscript number (if known):	TLCR-21-259	
relate part to trelate man. The to the med. In it.	ted to the content of your miles whose interests may be cansparency and does not not it in the property of the	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do so the author's relationship wities/interests should be dension, you should declare a tion is not mentioned in the	s/activities/interests as they relate to the <u>current</u> <u>efined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
	time frame for disclosure is	·	,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

			I
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11		V. Name	
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other services		
12	Other financial or non-	V. None	
13	Other financial or non- financial interests	XNone	
	imancial interests		

Chenchu Zhu has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

You	e:May 10 th , 2021 r Name: Jianfei Shen nuscript Title:_ A narrative r	eview of primary research	endpoints of neoadjuvant therapy for lung cancer: past,
-	ent and future uscript number (if known):	TLCR-21-259	
relat part to tr	ted to the content of your m ies whose interests may be	nanuscript. "Related" mear affected by the content of ecessarily indicate a bias. I	elationships/activities/interests listed below that are any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment f you are in doubt about whether to list a so.
	following questions apply to uscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>
to th	- ·	nsion, you should declare a	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive manuscript.
	em #1 below, report all supp time frame for disclosure is	· · · · · · · · · · · · · · · · · · ·	in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

			I
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11		V. Name	
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other services		
12	Other financial or non-	V. None	
13	Other financial or non- financial interests	XNone	
	imancial interests		

Jianfei Shen has no conflicts of interest to declare.

Please place an "X" next to the following statement to indicate your agreement: